Words for clinical notes
Search 5,131 terms by clinical wording, everyday description, or note example.
| Word | Plain-English search cue | Original note example | SOAP section | Writing task |
|---|---|---|---|---|
factor VIII activity | functional activity of factor eight in a coagulation assay | Factor VIII activity was reported with the specimen collection time. | Objective | Coagulation, antibodies and hemostasis studies |
factor IX activity | functional activity of factor nine in a coagulation assay | Factor IX activity was measured before the documented replacement dose. | Objective | Coagulation, antibodies and hemostasis studies |
factor XI activity | functional activity of factor eleven in plasma | Factor XI activity was included in the evaluation of the prolonged clotting time. | Objective | Coagulation, antibodies and hemostasis studies |
factor XIII activity | measure of the clot-stabilizing activity of factor thirteen | Factor XIII activity was reported independently of the routine clotting times. | Objective | Coagulation, antibodies and hemostasis studies |
von Willebrand factor antigen | quantity of von Willebrand factor measured in plasma | The von Willebrand factor antigen was paired with an activity assay. | Objective | Coagulation, antibodies and hemostasis studies |
von Willebrand factor activity | measure of a specified function of von Willebrand factor | Von Willebrand factor activity was interpreted with the antigen level and assay method. | Objective | Coagulation, antibodies and hemostasis studies |
multimer analysis | assessment of the distribution of von Willebrand factor molecules by size | Multimer analysis showed a reduction in high-molecular-weight bands. | Objective | Coagulation, antibodies and hemostasis studies |
thrombin time | time for clot formation after thrombin is added to plasma | Thrombin time was prolonged on the specimen drawn before the infusion. | Objective | Coagulation, antibodies and hemostasis studies |
reptilase time | time for clot formation after addition of a thrombin-like venom enzyme | Reptilase time was recorded alongside thrombin time. | Objective | Coagulation, antibodies and hemostasis studies |
lupus anticoagulant assay | phospholipid-dependent testing for a circulating inhibitor | The lupus anticoagulant assay was reviewed with the current anticoagulant exposure. | Objective | Coagulation, antibodies and hemostasis studies |
dilute Russell viper venom time | venom-based clotting assay used in lupus anticoagulant testing | Dilute Russell viper venom time was reported with screening and confirmation results. | Objective | Coagulation, antibodies and hemostasis studies |
anticardiolipin antibody | antibody directed against a cardiolipin-containing target | The anticardiolipin antibody was reported with isotype and measurement units. | Objective | Coagulation, antibodies and hemostasis studies |
beta-2 glycoprotein I antibody | antibody against beta-2 glycoprotein I | The beta-2 glycoprotein I antibody was listed separately from the anticardiolipin result. | Objective | Coagulation, antibodies and hemostasis studies |
antithrombin activity | functional measure of the plasma inhibitor antithrombin | Antithrombin activity was interpreted with the timing of the acute thrombosis. | Objective | Coagulation, antibodies and hemostasis studies |
protein C activity | functional measure of the natural anticoagulant protein C | Protein C activity was reviewed with the medication list. | Objective | Coagulation, antibodies and hemostasis studies |
free protein S antigen | quantity of the unbound form of protein S | The free protein S antigen was reported with the applicable reference interval. | Objective | Coagulation, antibodies and hemostasis studies |
activated protein C resistance | reduced anticoagulant response to activated protein C in a functional assay | Activated protein C resistance was reported with a comment on assay interference. | Objective | Coagulation, antibodies and hemostasis studies |
platelet aggregation study | measurement of platelet response to selected activating agents | The platelet aggregation study was reviewed with recent antiplatelet exposure. | Objective | Coagulation, antibodies and hemostasis studies |
clot lysis | breakdown of a formed clot during a hemostasis assay | Clot lysis was quantified over the specified observation period. | Objective | Coagulation, antibodies and hemostasis studies |
maximum clot firmness | peak clot strength on a rotational viscoelastic tracing | Maximum clot firmness was recorded for the specified assay channel. | Objective | Coagulation, antibodies and hemostasis studies |
clotting time on viscoelastic testing | time until the tracing reaches its defined initial clot endpoint | Clotting time on viscoelastic testing was reported with the instrument and test channel. | Objective | Coagulation, antibodies and hemostasis studies |
fibrin degradation products | fragments released during breakdown of fibrin or fibrinogen | Fibrin degradation products were measured with the laboratory method documented. | Objective | Coagulation, antibodies and hemostasis studies |
factor replacement recovery | measured increase in factor activity following an administered factor dose | Factor replacement recovery was assessed using paired baseline and timed samples. | Objective | Coagulation, antibodies and hemostasis studies |
platelet function assay | test of how well platelets respond under defined conditions | The platelet function assay was interpreted with the platelet count. | Objective | Coagulation, antibodies and hemostasis studies |
carcinoma in situ | malignant epithelial cells confined to their site of origin without stromal invasion | The pathology report documents carcinoma in situ with the involved surface specified. | Objective | Tissue pathology and cancer reporting |